Contact
QR code for the current URL

Press release Box-ID: 866401

GILUPI GmbH Hermannswerder 20a 14473 Potsdam, Germany http://www.gilupi.com
Contact Ms Dr. Claudia Chudak +49 331 58184785
Company logo of GILUPI GmbH
GILUPI GmbH

Detection of circulating tumor cells in breast cancer patients using the GILUPI CellCollector®

(PresseBox) (Potsdam, )
GILUPI GmbH announces that a scientific article about a multicenter, clinical trial in China has been published in the current issue of "National Medical Journal of China". The scientific paper demonstrates the isolation of circulating tumor cells (CTCs) from blood of breast cancer patients with the GILUPI CellCollector® [1].

Isolating and analyzing CTCs from the blood of cancer patients can provide additional information on prognosis of patients, treatment efficacy and molecular tumor evolution. Li and further colleagues from four different cancer centers in China investigated the prognostic relevance of CTCs in metastatic breast cancer (MBC). For this purpose the unique and innovative GILUPI CellCollector® in vivo technology was included in this clinical trial.

From April to August 2016, 127 patients diagnosed with metastatic breast cancer and 63 patients diagnosed with benign breast disease were enrolled. MBC patients received a GILUPI CellCollector® application before treatment and approximately 4 weeks after starting treatment, while benign patients had one GILUPI CellCollector® application.

Published data are already available for CTC isolation using the GILUPI CellCollector® technology in patients with prostate cancer, neuroendocrine tumors and lung cancer with high positivity rates (54 – 97%). In addition, this chinese study revealed for the first time, a high incidence of CTCs in newly progressive metastatic breast cancer patients. In metastatic breast cancer group 74.8% were positive for CTCs and the number of CTC detected in the benign group was 0 in each case. More importantly, CTC rates detected by the GILUPI CellCollector® displayed a decrease after 4 weeks treatment to 45% positivity rate. Li et al. showed also that the captured CTCs could be characterized on a molecular level. In conclusion, the researchers revealed a high specificity and sensitivity of CTCs as prognostic value.

[1] Li et al. "Circulating tumor cells in patients with breast tumors were detected by a novel device: a multicenter, clinical trial in China”, Zhonghua Yi Xue Za Zhi. 2017 Jun 27;97(24):1857-1861. doi: 10.3760/cma.j.issn.0376-2491.2017.24.003. Article in Chinese; For English version please contact GILUPI

Website Promotion

Website Promotion
GILUPI Website
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2022, All rights reserved

The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.